Mergers and Innovation in the Pharmaceutical Market

DSpace/Manakin Repository

Mergers and Innovation in the Pharmaceutical Market

Citable link to this page


Title: Mergers and Innovation in the Pharmaceutical Market
Author: Comanor, William S.; Scherer, Frederic Michael

Note: Order does not necessarily reflect citation order of authors.

Citation: Comanor, William S., and F.M. Scherer. 2011. Mergers and Innovation in the Pharmaceutical Market. HKS Faculty Research Working Paper Series RWP11-043, John F.Kennedy School of Government, Harvard University.
Full Text & Related Files:
Abstract: The U.S. pharmaceutical industry has experienced in recent years two dramatic changes: stagnation in the growth of new molecular entities approved for marketing, and a wave of mergers linking inter alia some of the largest companies. This paper explores possible links between these two phenomena and proposes alternative approach to merger policy. It points to the high degree of uncertainty encountered in the discovery and development of new pharmaceutical entities and shows how optimal strategies entail the pursue of parallel research and development paths. Uncertainties afflict both success rates and financial gains contingent upon success. A new model simulating optimal strategies given prevalent market uncertainties is presented. Parallelism can be sustained both within individual companies’ R&D programs and across competing companies. The paper points to data showing little parallelism of programs within companies and argues that inter-company mergers jeopardize desirable parallelism across companies.
Published Version:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search